Cardiac resynchronisation therapy in heart failure
Abstract
Abstract: Cardiac resynchronisation therapy (CRT) is a new therapeutic approach for a selected group of patients with symptomatic heart failure (NYHA III-IV) despite optimal medical therapy, due to dilated cardiomyopathy of any etiology (LVEF≤ 35%, and LVEDD≥ 55 mm), who present with electro-mechanical dyssynchrony (QRS≥ 120 msec). Safety and effectiveness of CRT have been demonstrated by several clinical trials, with patients achieving significant improvement in both clinical symptoms as well as functional status and exercise capacity. Furthermore, CRT has reduced morbidity and mortality of heart failure patients. Whether or not heart failure patients candidate to CRT should receive a defibrillator (ICD) back-up remains debatable, although growing evidence is pointing to extensive use of a defibrillator in such a population.
Downloads
References
Merit-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7.
Rodeheffer RJ, Naftel DC, Stevenson LW, et al. Secular trends in cardiac transplant recipient and donor management in the United States, 1990 to 1994. Circulation 1996; 94: 2883–9.
Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimised cardiac resynchronisation therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026–33.
Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344: 873–80.
Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronisation in chronic heart failure. N Engl J Med 2002; 346: 1902–5.
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140–50.
McAlister FA, Ezekowitz JA, Wiebe N, et al. Systematic review: cardiac resynchronisation in patients with symptomatic heart failure. Ann Intern Med 2004; 141: 381–90.
Bradley DJ, Bradley EA, Baughman KL, et al. Cardiac resynchronization and death from progressive heart failure. A Meta-analysis of randomized controlled trials. JAMA 2003; 289: 730–40.
Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539–49.
Liu L, Tockman B, Girouard S, et al. Left ventricular resynchronization therapy in a canine model of left bundle branch block. Am J Physiol Heart Circ Physiol 2002; 282: H2238–44.
Grines CL, Bashore TM, Boudoulas H, et al. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. Circulation 1989; 79: 845–53.
Kass DA. Ventricular resynchronization: Pathophysiology and identification of responders. Rev Cardiovasc Med 2003; 4: S3–13.
Meisner JS, McQueen DM, Shida Y, et al. Effects of timing of atrial systole on LV filling and mitral valve closure : computer and dog studies. Am J Phisiol 1985; 249: H604–19.
Baldasseroni S, Opasich C, Gorini M, et al. Left bundle branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian Network on Congestive Heart Failure Investigators. Am Heart J 2002; 143: 398–405.
Hesse B, Diaz LA, Snader CE, et al. Complete bundle branch block as an independent predictor of all-cause mortality: report of 7,073 patients referred for nuclear exercise testing. Am J Med 2001; 110: 253–59.
Auricchio A, Abraham WT. Cardiac resynchronisation therapy: Current state of the art. Cost versus benefit. Circulation 2004; 109: 300–7.
Fauchier L, Marie O, Casset-Senon D, et al. Interventricular and intraventricular dyssynchrony in idiopathic dilated cardiomyopathy. A prognostic study with Fourier phase analysis of radionuclide angioscintigraphy. J Am Coll Cardiol 2002; 40: 2022–30.
Rodriguez L-M, Timmermans C, Nabar A, et al. Variable patterns of septal activation in patients with left bundle branch block and heart failure. J Cardiovasc Electrophysiol 2003; 14: 135–41.
Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundle branch block. Circulation 2004; 109: 1133–9.
Fung JWH, Yu CM, Yip G, et al. Variable left ventricular activation pattern in patients with heart failure and left bundle branch block. Heart 2004; 90: 17–9.
Prinzen FW, Hunter WC, Wyman BT, et al. Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging. J Am Coll Cardiol 1999; 33: 1735– 42.
Spragg D, Leclercq C, Loghmani M, et al. Regional alterations in protein expression in the dyssynchronus failing heart. Circulation 2003; 108: 929– 32.
Ukkonen H, Beanlands RS, Burwash IG, et al. Effect of cardiac resynchronization on myocardial efficiency and regional oxidative metabolism. Circulation. 2003; 107: 28–31
Van Oosterhout FM, Prinzen FW, Arts T, et al. Asynchronous electrical activation induces asymmetrical hypertrophy of the left ventricular wall. Circulation 1998; 98: 588–95.
Prinzen FW, Van Oosterhout FM, Arts T, et al. Mismatch of local myocardial growth and blood flow during chronic ventricular pacing. Circulation 2000; 102: 196.
Nelson G, Berger RD, Fetics BJ, et al. Left or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle branch block. Circulation 2000; 102: 3053–59.
Yu CM, Chau E, Sanderson JE, et al. Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 2002; 105: 438–45.
Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Circulation 2003; 108: 2596–603.
Adamson PB, Smith AL, Abraham WT, et al. Continuous autonomic assessment in patients with symptomatic heart failure. Prognostic value of heart rate variability measured by an implanted cardiac resynchronisation device. Circulation 2004; 110: 2389–94.
Saxon LA, Boehmer JP, Hummel J, et al. Biventricular pacing in patients with congestive heart failure : two prospective randomised trials. The VIGOR CHF and VENTAK CHF Investigators. Am J Cardiol 1999; 83: 120D–3D.
Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/ AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation 2002; 106: 2145–61.
Butter C, Auricchio A, Stellbrink C, et al. Should stimulation site be tailored in the individual heart failure patient. Am J Cardiol 2000; 86: K144–51.
Yu CM, Lin H, Zhang Q, et al. High prevalence of left ventricular systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. Heart 2003; 89: 54–60.
Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronisation in patients with congestive heart failure and chronic atrial fibrillation: effects to upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002; 39: 1258–63.
Wilkoff BL, Cook JR, Epstein AE, et al. Dual-chamber pacing or ventricular back-up pacing in patients with an implantable defibrillator: the dual chamber and VVI implantable defibrillator (DAVID) trial. JAMA 2002; 288: 3115–23.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225–37.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
